The ceremony took place at the National Velodrome of Saint-Quentin-en-Yvelines. This trophy, awarded by Crédit Mutuel, highlights SQY Therapeutics' innovative projects and its role in local economic and scientific development.
This distinction follows a previous award, the 'Industrial Gem of Tomorrow' trophy, received in November 2025. The SQY Therapeutics team is currently developing treatments for rare diseases, with an advanced program in clinical development for Duchenne muscular dystrophy.
Founded in 2015 and originating from the academic research of the University of Versailles Saint-Quentin-en-Yvelines, the company utilizes a technological platform based on antisense oligonucleotides (ASOs) to offer new therapeutic approaches for rare diseases.
These two distinctions honor the work of the entire team and underscore the importance of health biotechnology within the scientific and economic ecosystem of the Yvelines.
The company thanked the organizers, the jury, and Crédit Mutuel for this recognition, as well as its partners and supporters.
